Jane Visit 1 - Postmenopausal woman with suspected metastatic breast cancer
| Title: | Jane Visit 1 - Postmenopausal woman with suspected metastatic breast cancer |
| Topic: | Oncology/ Hematology |
| Relevant Terms: | Breast Cancer, Oncology |
| Primary Audience: | Oncologists and other health care professionals who treat and care for patients with breast cancer. |
| Launch Date: | 17-Dec-09 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | 16-Dec-10 |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Interpret results from new and existing HER2 testing methodologies to determine appropriate treatment decisions
- Differentiate between the prognostic and predictive implications associated with HER2 positivity
- Compare and contrast monoclonal antibodies and tyrosine kinase inhibitors available for the treatment of HER2-positive breast cancer
- Apply evidence-based clinical trial data on new and emerging treatment strategies to ensure optimal care for patients with HER2-positive breast cancer
- Monitor and manage treatment-related toxicities associated with chemotherapeutic and biologic agents used to treat HER2-positive breast cancer
Faculty
Monica N. Fornier, MD
Assistant Professor of Medicine
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Patrick G. Morris, MD, MSc
Special Fellow in Breast Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York
Assistant Professor of Medicine
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Patrick G. Morris, MD, MScSpecial Fellow in Breast Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York
Disclosure Summary
education | outcomes | science is a CME provider accredited by the ACCME. In compliance with the Standards for Commercial Support, it is our policy to require everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest occurring within the 12 months prior to an activity's release date. The staff of education | outcomes | science involved with this activity have reported no relevant financial relationships with commercial interests.
Activity Faculty
Monica N. Fornier, MD has nothing to disclose.
Patrick G. Morris, MD, MSc has received speaker's bureau honoraria from Genentech.
Cleveland Clinic Foundation Activity Co-Chair
G. Thomas Budd, MD, Professor of Medicine, The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, discloses he has received honoraria for serving on an advisory board for Genentech.
Accreditation Statement/Designation of Credit
education | outcomes | science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
education | outcomes | science designates this educational activity for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To Obtain CME Credits
• Read the learning objectives and faculty disclosures.
• Participate in the activity.
• Complete the post-test and activity evaluation.
• Physicians who successfully complete the post-test and evaluation will receive CME credit.
• You must score 70% or higher on the post-test to receive credit for this activity.
• All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| PC Internet Explorer (v6 or greater), or Firefox |
MAC or Safari |
Supported by an unrestricted educational grant from Genentech, Inc.
Co-sponsored by
and 
The EOS privacy statement is available at: http://eoscme.org/Privacy.aspx?section=ce
Copyright © 2009 education | outcomes | science. All rights reserved.
711 Third Avenue, 11th Floor | New York, NY 10017 | 212.849.7700 | info@eoscme.org
